Plozasiran
Plozasiran, sold under the brand name Redemplo, is a medication used for the treatment of familial chylomicronemia syndrome.
≈ 1 min read
Names in other languages
No names in other languages are held for this entry yet.
Article bodies are English and are not machine-translated. A name in another language is not a translation of the article.
Plozasiran, sold under the brand name Redemplo, is a medication used for the treatment of familial chylomicronemia syndrome. Plozasiran is an apolipoprotein C-III (apoC-III)-directed small interfering ribonucleic acid (siRNA). It is given by injection under the skin (subcutaneously).
Plozasiran was approved for medical use in the United States in November 2025. The US Food and Drug Administration considers it to be a first-in-class medication.
Text derived from https://en.wikipedia.org/w/index.php?oldid=1365073615 under CC BY-SA 4.0; modifications have been made.